Regeneron Pharmaceuticals, Inc.

WBAG:REGN Stock Report

Market Cap: €77.4b

Regeneron Pharmaceuticals Valuation

Is REGN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REGN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REGN (€701.2) is trading below our estimate of fair value (€2145.54)

Significantly Below Fair Value: REGN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REGN?

Key metric: As REGN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for REGN. This is calculated by dividing REGN's market cap by their current earnings.
What is REGN's PE Ratio?
PE Ratio17.2x
EarningsUS$4.65b
Market CapUS$81.98b

Price to Earnings Ratio vs Peers

How does REGN's PE Ratio compare to its peers?

The above table shows the PE ratio for REGN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.1x
CSL CSL
32.8x13.0%AU$131.4b
AMGN Amgen
35.6x19.1%US$150.5b
BIIB Biogen
14x12.4%US$22.6b
ABBV AbbVie
57.9x28.1%US$294.4b
REGN Regeneron Pharmaceuticals
17.2x7.6%€82.0b

Price-To-Earnings vs Peers: REGN is good value based on its Price-To-Earnings Ratio (17.2x) compared to the peer average (35x).

Price to Earnings Ratio vs Industry

How does REGN's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
REGN 17.2xIndustry Avg. 27.3xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: REGN is good value based on its Price-To-Earnings Ratio (17.2x) compared to the European Biotechs industry average (26.9x).

Price to Earnings Ratio vs Fair Ratio

What is REGN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REGN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate REGN's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REGN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€701.20
€1,017.95
+45.2%
12.6%€1,161.37€755.36n/a26
Nov ’25€783.00
€1,010.87
+29.1%
11.1%€1,135.04€738.24n/a25
Oct ’25€944.80
€1,036.81
+9.7%
11.7%€1,164.28€734.39n/a25
Sep ’25€1,065.50
€1,038.46
-2.5%
12.0%€1,170.52€724.82n/a25
Aug ’25€1,018.50
€1,036.99
+1.8%
12.9%€1,204.71€667.22n/a25
Jul ’25€985.80
€984.36
-0.1%
12.1%€1,145.18€670.90n/a25
Jun ’25€898.40
€965.10
+7.4%
11.7%€1,091.62€663.26n/a25
May ’25€835.40
€967.70
+15.8%
11.2%€1,108.39€671.18n/a25
Apr ’25€892.00
€940.83
+5.5%
11.3%€1,089.75€653.48n/a25
Mar ’25€911.50
€931.15
+2.2%
11.8%€1,091.65€654.62n/a23
Feb ’25€879.00
€894.07
+1.7%
11.8%€1,038.71€655.54n/a24
Jan ’25€801.00
€828.25
+3.4%
11.6%€1,013.06€630.35n/a24
Dec ’24€754.00
€829.16
+10.0%
10.7%€972.83€620.57n/a25
Nov ’24€742.50
€854.36
+15.1%
10.6%€1,007.40€643.82€783.0023
Oct ’24€781.00
€850.24
+8.9%
10.5%€993.20€643.21€944.8023
Sep ’24€775.00
€821.99
+6.1%
10.8%€963.69€610.34€1,065.5023
Aug ’24€670.50
€776.12
+15.8%
10.6%€945.52€588.12€1,018.5023
Jul ’24€651.50
€790.56
+21.3%
11.7%€957.43€595.53€985.8023
Jun ’24€687.00
€824.66
+20.0%
10.9%€979.76€606.52€898.4023
May ’24€709.50
€796.28
+12.2%
10.5%€942.55€589.10€835.4023
Apr ’24€751.60
€803.74
+6.9%
10.9%€958.78€599.24€892.0023
Mar ’24€715.50
€776.86
+8.6%
12.2%€945.39€565.74€911.5023
Feb ’24€693.30
€743.77
+7.3%
12.5%€943.10€557.75€879.0023
Jan ’24€672.80
€755.70
+12.3%
13.0%€968.87€561.32€801.0023
Dec ’23€731.00
€756.03
+3.4%
13.3%€975.65€546.25€754.0023
Nov ’23€769.60
€790.31
+2.7%
13.4%€1,037.51€582.02€742.5023

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

ALM

€8.33

7D

-0.5%

1Y

-2.4%

Teva Pharmaceutical Industries

US$18.7b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$15.70

7D

-3.1%

1Y

81.3%

Bayer

€19.8b

Together its subsidiaries, operates as a life science company worldwide.

BAYN

€20.07

7D

-2.9%

1Y

-40.9%